About

About OrgaNova OrgaNova is a biotechnology company advancing next-generation human organoid platforms for cancer research and translational applications. We develop patient-derived and iPSC-derived organoid models using our Organoid 2.0 approach designed to better preserve native tumor architecture, cellular heterogeneity, and key microenvironmental features. OrgaNova is building a comprehensive organoid biobank and provides organoid-based CRO services, including drug screening, toxicity testing, and functional response profiling to support precision oncology and preclinical development. With operations in Philadelphia and collaborative capabilities in China, we enable scalable, high-quality organoid generation and testing to accelerate discovery and improve the predictive power of human-relevant models.